Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report. Issue 1 (December 2017)

• Record Type: Journal Article
• Authors: Paraghamian, Sarah; Longoria, Teresa; Eskander, Ramez
• Is Part Of: Gynecologic oncology research and practice. Volume 4:Issue 1(2017)
• Page Start: 1
• Page End: 5
• Publication Date: 2017-12
• Subjects: Small cell neuroendocrine carcinoma -- Cervical cancer -- PD-1 inhibitor -- Nivolumab -- Immunotherapy; Gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 616.9946
• DOI: 10.1186/s40661-017-0038-9
• Languages: English
• ISSNs: 2053-6844

Abstract

Abstract Background Nivolumab is an immune checkpoint inhibitor specific for the programmed death 1 (PD-1) receptor that has led to clinical responses in many cancer types. Identifying biomarkers predictive of response to PD-1 blockade is an area of active investigation. Case presentation We present a patient with recurrent, metastatic, PD-L1-negative small cell neuroendocrine carcinoma of the cervix (SCNEC) who experienced a complete response to nivolumab. Though nivolumab was discontinued over 4 months ago due to treatment-related adverse events, she continues to have no evidence of disease. Conclusions Immune checkpoint inhibitors may be active in neuroendocrine cervical cancer, with potential for dramatic responses in a modest subset of patients.